These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 26807548

  • 21. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
    Zhang Y, Guo G, Ma B, Du R, Xiao H, Yang X, Li W, Gao Y, Li Y, Jing X.
    Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
    [Abstract] [Full Text] [Related]

  • 22. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG, Pan ZY, Zhang DY, Cao Q, Ji LN, Mao ZW.
    ACS Appl Mater Interfaces; 2020 Sep 30; 12(39):43444-43455. PubMed ID: 32883070
    [Abstract] [Full Text] [Related]

  • 23. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J.
    Biomaterials; 2018 Feb 30; 155():112-123. PubMed ID: 29175080
    [Abstract] [Full Text] [Related]

  • 24. A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells.
    Yuan Y, Zhang CJ, Liu B.
    Chem Commun (Camb); 2015 May 21; 51(41):8626-9. PubMed ID: 25898264
    [Abstract] [Full Text] [Related]

  • 25. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
    Lee KGZ, Babak MV, Weiss A, Dyson PJ, Nowak-Sliwinska P, Montagner D, Ang WH.
    ChemMedChem; 2018 Jun 20; 13(12):1210-1217. PubMed ID: 29637702
    [Abstract] [Full Text] [Related]

  • 26. Advances in platinum chemotherapeutics.
    Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR.
    Chemistry; 2010 Jun 25; 16(24):7064-77. PubMed ID: 20533453
    [Abstract] [Full Text] [Related]

  • 27. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U.
    J Control Release; 2008 Oct 21; 131(2):100-6. PubMed ID: 18691617
    [Abstract] [Full Text] [Related]

  • 28. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of nanoparticle delivered cisplatin in beagles.
    Feldhaeusser B, Platt SR, Marrache S, Kolishetti N, Pathak RK, Montgomery DJ, Reno LR, Howerth E, Dhar S.
    Nanoscale; 2015 Sep 07; 7(33):13822-30. PubMed ID: 26234400
    [Abstract] [Full Text] [Related]

  • 30. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
    Fang T, Ye Z, Wu J, Wang H.
    Chem Commun (Camb); 2018 Aug 14; 54(66):9167-9170. PubMed ID: 30062328
    [Abstract] [Full Text] [Related]

  • 31. The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions.
    Gabano E, Ravera M, Trivero F, Tinello S, Gallina A, Zanellato I, Gariboldi MB, Monti E, Osella D.
    Dalton Trans; 2018 Jun 25; 47(25):8268-8282. PubMed ID: 29892758
    [Abstract] [Full Text] [Related]

  • 32. Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II).
    Xiao H, Qi R, Liu S, Hu X, Duan T, Zheng Y, Huang Y, Jing X.
    Biomaterials; 2011 Oct 25; 32(30):7732-9. PubMed ID: 21783244
    [Abstract] [Full Text] [Related]

  • 33. Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.
    Medrano MÁ, Álvarez-Valdés A, Perles J, Lloret-Fillol J, Muñoz-Galván S, Carnero A, Navarro-Ranninger C, Quiroga AG.
    Chem Commun (Camb); 2013 May 25; 49(42):4806-8. PubMed ID: 23591566
    [Abstract] [Full Text] [Related]

  • 34. Strategy for Traceless Codrug Delivery with Platinum(IV) Prodrug Complexes Using Self-Immolative Linkers.
    Lee VEY, Lim ZC, Chew SL, Ang WH.
    Inorg Chem; 2021 Feb 01; 60(3):1823-1831. PubMed ID: 33464875
    [Abstract] [Full Text] [Related]

  • 35. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
    Corte-Rodríguez M, Espina M, Sierra LM, Blanco E, Ames T, Montes-Bayón M, Sanz-Medel A.
    Biochem Pharmacol; 2015 Nov 01; 98(1):69-77. PubMed ID: 26352094
    [Abstract] [Full Text] [Related]

  • 36. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
    Hall MD, Daly HL, Zhang JZ, Zhang M, Alderden RA, Pursche D, Foran GJ, Hambley TW.
    Metallomics; 2012 Jun 01; 4(6):568-75. PubMed ID: 22569908
    [Abstract] [Full Text] [Related]

  • 37. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
    Ravera M, Gabano E, Bonzani D, Zanellato I, Arrais A, Cantamessa S, Biggiogera M, Osella D.
    J Inorg Biochem; 2018 Dec 01; 189():185-191. PubMed ID: 30312905
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
    Wang X, Li L, Pei S, Zhu Q, Chen F.
    Pharmazie; 2020 Mar 20; 75(2):94-101. PubMed ID: 32213241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.